FGFR2-Positive Cholangiocarcinoma: Pemigatinib Now or Chemotherapy First
A newly diagnosed FGFR2 fusion-positive cholangiocarcinoma, and whether real trial evidence for first-line targeted therapy is reachable before her insurer has had a chance to say no.
Elena V., 58, retired six months ago from three decades of teaching high school French, planning to spend the extra time on the six-mile birding hikes she and her husband have kept up most weekends for years. Over the past three months those hikes have gotten shorter, then stopped — a vague fullness under her right ribs she blamed on getting older, plus twelve pounds she didn't try to lose. Imaging found a 4.3-centimeter mass in the fourth segment of her liver; biopsy confirmed intrahepatic cholangiocarcinoma. Comprehensive genomic profiling, now routine for any newly diagnosed advanced case, returned an FGFR2-BICC1 fusion — present in roughly 10 to 16 percent of intrahepatic cholangiocarcinomas, and the single most actionable finding this tumor could have handed the team. Her bilirubin, at 0.6 mg/dL, is unremarkable in isolation but matters directly here: it clears her for full-dose cisplatin, a drug whose real toxicity in biliary cancer is so often compounded by the cholestasis these patients already carry — cholestasis she doesn't have.
The tumor's location, encasing a segment of the portal vein, makes it unresectable; the plan from here is systemic therapy, and the fusion has turned what would otherwise be a single-path conversation into a genuine choice. FIGHT-302 randomized previously untreated, FGFR2 fusion-positive patients — not previously treated ones, not fusion-negative ones, patients matching her profile exactly — to pemigatinib against gemcitabine-cisplatin, and found a real progression-free-survival advantage for the targeted drug — 8.3 months against 6.8, hazard ratio 0.58. What it did not find was any overall-survival advantage: 24.4 months against 25.0, and the trial's own investigators concluded the result confirms giving pemigatinib after chemotherapy rather than instead of it. The complication is that pemigatinib's actual FDA approval, granted in 2020, still covers only previously treated disease; nothing about the FIGHT-302 result has yet changed what an insurer is obligated to authorize on a first prescription. Elena wants to know, directly, whether she can start "the newer one" before anything else — and whether waiting on an appeal is itself a decision with a cost, given how much of her stamina she's already lost. Her ECOG performance status of 0 — still walking her neighborhood daily even if the six-mile loop is out of reach for now — also matters beyond documenting fitness for chemotherapy: it's close to the baseline FIGHT-302's own enrolled patients carried, which is part of why the oncology team keeps returning to that trial specifically rather than reasoning from pemigatinib's original, more heavily pretreated approval population.
In the tumor board, before the first cycle is ordered
FIGHT-302 randomized previously-untreated, FGFR2 fusion-positive patients — her exact profile — to pemigatinib versus gemcitabine-cisplatin, and the pemigatinib arm's progression-free survival came out ahead, 8.3 months to 6.8; when a trial's enrolled population is this specific, using the result to inform someone outside that population is the extrapolation, not using it for someone inside it. He'll concede the survival curves came together — but progression-free survival is what the trial was powered for, and it's also what buys her the months she's asking about.
Pemigatinib's oral dosing and different toxicity profile — central serous retinopathy and hyperphosphatemia rather than cytopenias — is also a real quality-of-life consideration for someone three months into losing the stamina for a six-mile hike.
Doesn't dispute the trial data. Disputes that the data are reachable for her on day one. Pemigatinib's FDA label has not changed since its 2020 accelerated approval — it covers previously treated disease only — and prescribing it first-line means a prior authorization built on an off-label indication, which insurers deny far more often than they approve, then weeks lost to appeal while she's already losing weight.
"Not an extrapolation" is true of the trial data; it says nothing about whether her insurer will read it the same way before a first dose is ever dispensed.
There's a way to not have to guess which of them is right before treatment starts — and FIGHT-302 itself points at it, since the one thing the trial did not show was that giving pemigatinib first extends life over giving it second. TOPAZ-1 established gemcitabine-cisplatin-durvalumab as first-line standard for advanced cholangiocarcinoma regardless of biomarker status — no appeal required, no delay, chemo can start this week. File the pemigatinib appeal in parallel; if it clears before she progresses, the plan changes to reflect it, and if it doesn't, pemigatinib is still guaranteed as her actual second line under the label everyone already agrees is solid. It isn't the fastest path to the FIGHT-302 result, but it's the only one of the three that doesn't ask her to wait on anything.
Agreed within the same tumor board: gemcitabine-cisplatin-durvalumab starts this week, and the pharmacist files the pemigatinib appeal the same day so any answer arrives well before a first restaging scan.
Not agreed: how hard to push the appeal if it's denied on first pass — the medical oncologist wants to escalate immediately with the FIGHT-302 data attached to a peer-to-peer review; the pharmacist thinks a first denial is often just a paperwork problem better solved by resubmission than by an urgent peer-to-peer that may not be granted quickly anyway. Left for whoever is managing the appeal when the denial letter actually arrives.